

## original article

*Diabetes, Obesity and Metabolism* 17: 1180–1193, 2015.© 2015 The Authors. *Diabetes, Obesity and Metabolism* published by John Wiley & Sons Ltd.

# Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

R. Chilton<sup>1</sup>, I. Tikkanen<sup>2</sup>, C. P. Cannon<sup>3</sup>, S. Crowe<sup>4</sup>, H. J. Woerle<sup>4</sup>, U. C. Broedl<sup>4</sup> & O. E. Johansen<sup>5</sup><sup>1</sup> Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA<sup>2</sup> Helsinki University Hospital and Minerva Institute for Medical Research, University of Helsinki, Helsinki, Finland<sup>3</sup> Department of Cardiology, Harvard Clinical Research Institute, Boston, MA, USA<sup>4</sup> Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany<sup>5</sup> Boehringer Ingelheim Norway KS, Asker, Norway

**Aims:** To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM).

**Methods:** We conducted a *post hoc* analysis of data from a phase III trial in patients with T2DM and hypertension receiving 12 weeks' empagliflozin and four phase III trials in patients with T2DM receiving 24 weeks' empagliflozin (cohort 1, n = 823; cohort 2, n = 2477). BP was measured using 24-h BP monitoring (cohort 1) or seated office measurements (cohort 2).

**Results:** Empagliflozin reduced systolic BP (SBP) and diastolic BP in both cohorts ( $p < 0.001$  vs placebo), without increasing heart rate. Empagliflozin reduced pulse pressure (PP; adjusted mean difference vs placebo cohort 1:  $-2.3$  mmHg; cohort 2:  $-2.3$  mmHg), mean arterial pressure (MAP; cohort 1,  $-2.3$  mmHg; cohort 2,  $-2.1$  mmHg) and double product (cohort 1,  $-385$  mmHg  $\times$  bpm; cohort 2,  $-369$  mmHg  $\times$  bpm) all  $p < 0.001$  vs placebo. There was a trend towards a reduction in the ambulatory arterial stiffness index (AASI) with empagliflozin in cohort 1 ( $p = 0.059$  vs placebo). AASI was not measured in cohort 2. Subgroup analyses showed that there were greater reductions in PP with increasing baseline SBP in cohort 1 ( $p = 0.092$ ). In cohort 2, greater reductions in MAP were achieved in patients with higher baseline SBP ( $p = 0.027$ ) and greater reductions in PP were observed in older patients ( $p = 0.011$ ).

**Conclusions:** Empagliflozin reduced BP and had favourable effects on markers of arterial stiffness and vascular resistance.

**Keywords:** cardiovascular disease, phase III study, SGLT2 inhibitor, type 2 diabetes

Date submitted 29 July 2015; date of first decision 20 August 2015; date of final acceptance 1 September 2015

## Introduction

Cardiovascular (CV) disease is the major cause of morbidity and mortality in patients with type 2 diabetes (T2DM) [1]. The risk of CV disease in adults with diabetes is double that in adults without diabetes, and diabetes is estimated to account for 10–12% of all vascular deaths [2]. Patients with T2DM often have numerous CV risk factors and a multifactorial approach to addressing CV risk, including controlling glycaemia, blood pressure (BP) and body weight, is recommended in these patients [1,3].

The metabolic abnormalities that are characteristic of diabetes, such as hyperglycaemia, excess free fatty acids and insulin resistance, can lead to suppression of nitric oxide production and activation of the renin-angiotensin system, leading to oxidative stress, endothelial dysfunction and activation of the receptor for advanced glycation end products (RAGE) [4–6]. These may contribute to hypertension [7] or to increased arterial stiffness related to vascular calcification or accumulation of

collagen [8,9] that could partly explain the increased risk of vascular complications associated with T2DM [4].

Arterial stiffness is a strong predictor of CV events, heart failure and death [10–12]. Although aortic pulse wave velocity is generally considered to be the 'gold standard' for non-invasive assessments of arterial stiffness, in clinical practice, pulse pressure (PP) can be used as a surrogate marker. PP is determined by cardiac output and the stiffness of elastic central arteries, such as the aorta, and may be calculated as the difference between systolic BP (SBP) and diastolic BP (DBP) [13]. Increased peripheral PP is an independent predictor of CV disease in patients with T2DM [14–16], and a meta-analysis showed that the relative risks of CV events were similar for an increase in central SBP and central PP to those for their peripheral (brachial) counterparts [17]. Another marker of arterial stiffness is the ambulatory arterial stiffness index [AASI: 1 minus the regression slope of DBP and SBP values derived from 24-h ambulatory BP monitoring (ABPM) [18]]. The AASI represents the dynamic relationship between SBP and DBP, as defined by haemodynamic arterio-ventricular properties, and has been reported to be an independent predictor of CV mortality [19].

Mean arterial pressure (MAP) is a measure of central haemodynamics that reflects the cardiac cycle and is determined by cardiac output, systemic vascular resistance and

Correspondence to: Odd Erik Johansen, Boehringer Ingelheim Norway KS, Asker, Norway.  
E-mail: [odd\\_erik.johansen@boehringer-ingelheim.com](mailto:odd_erik.johansen@boehringer-ingelheim.com)

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

central venous pressure. MAP is calculated as  $2/3 \text{ DBP} + 1/3 \text{ SBP}$  [16] and has been shown to be predictive of CV events in patients with T2DM.

The myocardium's workload is related to vascular stiffness and cardiac function, and one variable that quantifies this is the double product (DP), also known as the rate pressure product (RPP). This is calculated as  $\text{heart rate} \times \text{SBP}$  and provides an indirect measure of myocardial oxygen demand. Chronic elevations of DP, representing an increased cardiac load, may cause long-term cardiac impairment and DP is associated with CV complications, CV mortality and non-CV mortality [20,21].

Empagliflozin is a potent and selective sodium glucose cotransporter 2 (SGLT2) inhibitor [22] used in the treatment of T2DM. In phase III trials, empagliflozin (10 and 25 mg) improved glycaemic control with a low risk of hypoglycaemia, and was associated with reductions in BP and body weight [23–27]. In a 4-week study in patients with T2DM, empagliflozin monotherapy reduced oxidative stress, as shown by reductions in 8-iso-prostaglandin $2\alpha$ , and also improved daily blood glucose control [28]. Empagliflozin has been shown to have central haemodynamic effects: in patients with type 1 diabetes (T1DM), empagliflozin reduced arterial stiffness assessed by measurement of carotid-radial pulse wave velocity and radial, carotid and aortic augmentation indices [29].

To determine the effects of empagliflozin on markers of arterial stiffness (PP and AASI) and arterial resistance (MAP) in patients with T2DM, we analysed data from five phase III studies. We also determined the effects of empagliflozin on indirect determinants of myocardial oxygen demand and hence the workload on the heart (heart rate, BP and DP). Further, we conducted subgroup analyses to test our hypothesis that empagliflozin would reduce BP, PP and MAP across subgroups defined by age, sex and degree of hypertension at baseline, with greater reductions in older patients and those with the highest SBP at baseline.

## Methods

### Study Design and Patients

Data from two cohorts of patients, one treated with empagliflozin for 12 weeks (cohort 1) and one treated with empagliflozin for 24 weeks (cohort 2), were analysed. Cohort 1 comprised patients from the EMPA-REG BP<sup>TM</sup> trial [27]. Patients had T2DM with hypertension (mean seated office SBP 130–159 mmHg and DBP 80–99 mmHg), glycated haemoglobin (HbA1c)  $\geq 7$  and  $\leq 10\%$  ( $\geq 53$  and  $\leq 86$  mmol/mol) and a body mass index  $\leq 45$  kg/m<sup>2</sup> at baseline. Patients were either drug-naïve [had not received any oral glucose-lowering therapy, glucagon-like peptide-1 (GLP-1) analogue, or insulin for  $\geq 12$  weeks ( $\geq 16$  weeks for pioglitazone) before randomization] or had been receiving stable doses of glucose-lowering therapy [oral agents or GLP-1 analogue at doses unchanged for  $\geq 12$  weeks ( $\geq 16$  weeks for pioglitazone) before randomization, or insulin at dose changed by  $\leq 10\%$  for  $\geq 12$  weeks before randomization] [27]. Patients were required to have been receiving no, one or two BP-lowering medications at a stable dose for  $\geq 4$  weeks at screening and throughout a 2-week placebo run-in period. Patients were randomized to receive

empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily for 12 weeks. Patients underwent 24-h ABPM  $\leq 7$  days before randomization and at week 12 [27]. During the treatment period, patients continued their background BP-lowering therapy at an unchanged dose, but changes in BP-lowering medication could be initiated if a patient had a mean SBP  $\geq 160$  mmHg and/or a mean DBP  $\geq 100$  mmHg at a clinic visit.

Cohort 2 comprised patients from the four pivotal trials of empagliflozin required for regulatory submissions: EMPA-REG MONO<sup>TM</sup> [23], EMPA-REG MET<sup>TM</sup> [24], EMPA-REG METSU<sup>TM</sup> [25] and EMPA-REG PIO<sup>TM</sup> [26]. Patients in these trials had T2DM, HbA1c  $\geq 7$  and  $\leq 10\%$  ( $\geq 53$  and  $\leq 86$  mmol/mol) and a body mass index  $\leq 45$  kg/m<sup>2</sup>. Patients in the EMPA-REG MONO<sup>TM</sup> trial were drug-naïve (had not received glucose-lowering therapy for  $\geq 12$  weeks before randomization) [23]. Patients in the EMPA-REG MET<sup>TM</sup> or EMPA-REG METSU<sup>TM</sup> trials had received immediate-release metformin [ $\geq 1500$  mg/day, up to maximum tolerated dose (MTD) or maximum dose according to local label] unchanged for  $\geq 12$  weeks before randomization, or metformin plus a sulphonylurea ( $\geq 50\%$  of MTD, up to the MTD or maximum dose according to local label) unchanged for  $\geq 12$  weeks before randomization, respectively [24,25]. Patients in the EMPA-REG PIO<sup>TM</sup> trial had received pioglitazone ( $\geq 30$  mg/day, up to MTD or maximum dose according to local label) unchanged for  $\geq 12$  weeks before randomization, with or without metformin immediate release (as described above) [26]. In all four trials, patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo as monotherapy (EMPA-REG MONO<sup>TM</sup>) or add-on to background therapy for 24 weeks.

Glucose-lowering rescue medication could be initiated at the discretion of the investigator if, after an overnight fast, a patient had a confirmed plasma glucose level  $>13.3$  mmol/l during the first 12 weeks of treatment or, in the 24-week trials,  $>11.1$  mmol/l [or HbA1c  $>8.5\%$  (69 mmol/mol) in the EMPA-REG MET<sup>TM</sup> and EMPA-REG METSU<sup>TM</sup> studies] during weeks 12–24.

All studies were approved by the Institutional Review Boards and Independent Ethics Committees and Competent Authorities of the participating centres and complied with the Declaration of Helsinki in accordance with the International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice. All patients who participated in these studies provided written informed consent.

### Endpoints and Measurements

In the present *post hoc* analysis, the following endpoints were analysed in cohort 1: changes from baseline in HbA1c and in 24-h SBP and DBP, heart rate, PP, MAP, DP (or RPP) and AASI (based on 24-h ABPM measurements) at week 12. The following endpoints were analysed in cohort 2: changes from baseline in HbA1c, seated office SBP and DBP, heart rate, PP, MAP and DP (or RPP) at week 24.

In both cohorts, changes from baseline in SBP, DBP, PP and MAP were analysed in subgroups of patients by baseline age ( $<50$ , 50 to  $<65$ , 65 to  $<75$ ,  $\geq 75$  years), sex, and baseline SBP ( $<130$ , 130–140,  $>140$  mmHg). PP was calculated as

SBP – DBP (mmHg). MAP was calculated as  $2/3$  DBP +  $1/3$  SBP (mmHg). DP (or RPP) was calculated as heart rate (bpm)  $\times$  SBP (mmHg). AASI was calculated as 1 minus the regression slope of DBP on SBP during 24-h ABPM.

In light of the small/modest differences in the impact of empagliflozin 10 and 25 mg on reducing SBP and DBP [23–27], the two doses were pooled for the purpose of the present analyses.

### Statistical Analyses

For each cohort, data from patients in the empagliflozin 10 mg and empagliflozin 25 mg groups were pooled. Changes from baseline in each cohort were analysed using an analysis of covariance (ANCOVA) with baseline HbA1c and the baseline value of the endpoint in question (if not HbA1c) as linear covariates, and baseline estimated glomerular filtration rate (Modification of Diet in Renal Disease equation), region and treatment as fixed effects. The number of BP-lowering medications at baseline was an additional fixed effect in analysis of data from cohort 1. In cohort 2, the individual study was an additional fixed effect when analysing the data. Changes from baseline in SBP, DBP, PP and MAP in subgroups of baseline age, sex and baseline SBP were analysed using the same ANCOVA model, but including baseline age, sex and baseline SBP, respectively, as additional linear covariates and the corresponding treatment by subgroup of interest interaction. For cohort 1, baseline SBP was the baseline mean 24-h SBP value. Analyses were conducted on the full analysis set (FAS). For cohort 1, the FAS comprised randomized patients who received  $\geq 1$  dose of study drug and had a baseline HbA1c value and a baseline mean 24-h SBP value. For cohort 2, the FAS comprised randomized patients who received  $\geq 1$  dose of study drug and had a baseline HbA1c value. Values observed after initiation of glucose-lowering rescue therapy were set to missing. A last observation carried forward (LOCF) approach was used to impute missing data. Statistical analyses were performed using % data for HbA1c.

## Results

### Patients

Of 825 patients randomized in the EMPA-REG BP™ trial, 823 were included in the FAS for cohort 1 (empagliflozin:  $n = 552$ ; placebo:  $n = 271$ ). Of the 2482 patients randomized in the four 24-week phase III trials, 2477 patients were included in the FAS for cohort 2 (empagliflozin:  $n = 1652$ ; placebo:  $n = 825$ ). In each cohort, patient demographics and baseline characteristics were generally balanced between treatment groups (Table S1).

### Glycaemic Control

In both cohorts, empagliflozin significantly reduced HbA1c from baseline compared with placebo. In cohort 1, the adjusted mean  $\pm$  standard error (s.e.) change from baseline in HbA1c at week 12 was  $0.03 (\pm 0.04)\%$  [ $0.3 (\pm 0.4)$  mmol/mol] with placebo compared with  $-0.61 (\pm 0.02)\%$  [ $-6.7 (\pm 0.3)$  mmol/mol] with empagliflozin {adjusted mean difference vs placebo:  $-0.64\%$  [95% confidence interval (CI)  $-0.72, -0.55$ ] or  $-7.0$  mmol/mol (95% CI  $-7.9, -6.0$ );

$p < 0.001$ }. In cohort 2, the adjusted mean ( $\pm$  s.e.) change from baseline in HbA1c at week 24 was  $-0.08 (\pm 0.03)\%$  [ $-0.9 (\pm 0.3)$  mmol/mol] with placebo compared with  $-0.73 (\pm 0.02)\%$  [ $-8.0 (\pm 0.2)$  mmol/mol] with empagliflozin [adjusted mean difference vs placebo:  $-0.65\%$  (95% CI  $-0.71, -0.59$ ) or  $-7.1$  mmol/mol (95% CI  $-7.8, -6.4$ );  $p < 0.001$ ]. The proportions of patients with imputed data for change from baseline in HbA1c in cohort 1 at week 12 were 10.3 and 9.6% for patients treated with empagliflozin and placebo, respectively, whereas in cohort 2, the corresponding figures at week 24 were 12.2 and 25.7%.

### Blood Pressure and Heart Rate

In both cohorts, empagliflozin significantly reduced SBP and DBP from baseline compared with placebo. In cohort 1, the adjusted mean difference versus placebo in change from baseline in mean 24-h SBP at week 12 was  $-3.9$  mmHg (95% CI  $-5.0, -2.7$ ;  $p < 0.001$ ) and in mean 24-h DBP was  $-1.5$  mmHg (95% CI  $-2.2, -0.8$ ;  $p < 0.001$ ; Figure S1). In cohort 2, the adjusted mean difference versus placebo in change from baseline in SBP at week 24 was  $-3.6$  mmHg (95% CI  $-4.5, -2.7$ ;  $p < 0.001$ ) and in DBP was  $-1.3$  mmHg (95% CI  $-1.9, -0.8$ ;  $p < 0.001$ ; Figure S1). The adjusted mean difference versus placebo in change from baseline in mean 24-h heart rate was  $-0.6$  bpm (95% CI  $-1.4, 0.3$ ;  $p = 0.209$ ) in cohort 1 and  $-0.8$  bpm (95% CI  $-1.4, -0.2$ ;  $p = 0.012$ ) in cohort 2 (Figure S1). The proportions of patients with imputed data for change from baseline in SBP in cohort 1 at week 12 were 12.7 and 13.3% for patients treated with empagliflozin and placebo, respectively, whereas in cohort 2, the corresponding figures at week 24 were 11.6 and 25.1%.


### Markers of Arterial Stiffness and Vascular Resistance

Empagliflozin significantly ( $p < 0.001$ ) reduced PP, MAP and DP (or RPP) compared with placebo in both cohorts (Figure 1). In cohort 1, the reduction in AASI did not reach significance ( $p = 0.059$  for differences vs placebo).

**Subgroup Analyses: Baseline Age.** With increasing age, baseline SBP generally increased and baseline DBP generally decreased, hence baseline PP increased (Figure 2). Empagliflozin reduced SBP, DBP, PP and MAP compared with placebo in most subgroups by baseline age; however, none of the interaction  $p$  values reached significance ( $p < 0.1$ ) except for PP in cohort 2, which was reduced to a greater extent in older patients ( $p = 0.011$ ; Table 1).

**Subgroup Analyses: Sex.** In cohort 1, baseline SBP and DBP were higher in men than women (Figure 3). In cohort 2, baseline SBP was higher in men than women (Figure 3). Empagliflozin significantly reduced SBP, DBP, PP and MAP compared with placebo in both sexes (Table 1; Figure 3), with no significant interactions between sex and treatment responses.

**Subgroup Analyses: Baseline SBP.** Baseline DBP, PP and MAP increased with baseline SBP and empagliflozin significantly reduced SBP compared with placebo in all



**Figure 1.** Changes in markers of arterial stiffness and vascular resistance. (A) Change from baseline in pulse pressure (PP) at week 12 in cohort 1 and week 24 in cohort 2 [analysis of covariance (ANCOVA) using last observation carried forward (LOCF)]. (B) Change from baseline in mean arterial pressure (MAP) at week 12 in cohort 1 and week 24 in cohort 2 (ANCOVA, LOCF). (C) Change from baseline in double product (DP) or rate pressure product (RPP) at week 12 in cohort 1 and week 24 in cohort 2 (ANCOVA, LOCF). (D) Change from baseline in ambulatory arterial stiffness index (AASI) at week 12 in cohort 1. Data are adjusted mean ± standard error (s.e.) in the full analysis set. In cohort 1, measurements were based on mean 24-h ABPM and in cohort 2, they were based on seated office measurements.

subgroups (Figure 4), with significant treatment by baseline SBP interaction in cohort 2 (p=0.013; Table 1; Figure 4). Empagliflozin also significantly reduced DBP, PP and MAP in all baseline SBP subgroups, except for DBP in patients with baseline SBP >140 mmHg in cohort 1 (Table 1; Figure 4). There appeared to be greater reductions in PP with increasing baseline

SBP in both cohorts, although the treatment by baseline SBP interaction only reached significance in cohort 1 (p = 0.092 for treatment by baseline SBP interaction; Table 1). In cohort 2, there were greater reductions in MAP with increasing baseline SBP (p=0.027 for treatment by baseline SBP interaction; Table 1).





Figure 1. Continued

**Safety and Tolerability**

Data on the safety and tolerability of empagliflozin, including adverse events and changes in lipids and other laboratory variables, have been published for the individual trials [23–27]. In brief, empagliflozin was associated with an incidence of hypoglycaemia similar to placebo except when used in combination with a sulphonylurea. Events consistent with genital infection were reported in a higher proportion of patients receiving empagliflozin than placebo, while events consistent with urinary tract infection were reported by

a similar proportion of patients receiving empagliflozin and placebo. Events consistent with volume depletion were reported in 1 patient (0.4%) on placebo and 1 patient on empagliflozin (0.2%) in cohort 1, and 2 patients (0.2%) on placebo and 5 patients (0.3%) on empagliflozin in cohort 2; none of these events was reported in patients aged  $\geq 75$  years. Increases in HDL cholesterol with empagliflozin versus placebo were reported in four of the five studies [23–26], and two studies reported increases in LDL cholesterol with empagliflozin versus placebo [24,27].





**Figure 2.** Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) by subgroups of baseline age. (A) SBP, DBP, PP and MAP at baseline and at week 12 in cohort 1. (B) SBP, DBP, PP and MAP at baseline at week 24 in cohort 2. Baseline data are mean  $\pm$  standard error (s.e.), week 12 or 24 data are adjusted mean  $\pm$  s.e. based on analysis of covariance (ANCOVA) in the full analysis set using last observation carried forward (LOCF) imputation. In cohort 1, measurements were based on mean 24-h ambulatory blood pressure monitoring (ABPM) and in cohort 2, they were based on seated office measurements. \*\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$  for adjusted mean differences for empagliflozin versus placebo in change from baseline based on ANCOVA with LOCF imputation.

## Discussion

The objective of the present *post hoc* analysis was to explore the effects of empagliflozin on BP, arterial stiffness and vascular resistance in patients with T2DM. In both of the cohorts studied, empagliflozin reduced BP, without increasing heart rate, and had favourable effects on markers of arterial stiffness and vascular resistance as well as on a marker of myocardial workload.

The differences in baseline SBP, DBP and PP with increasing age were, as expected, based on population data. After the age of 50 years, SBP continues to increase, while DBP tends to remain fairly stable between ages 50 and 60 years and

then decrease, leading to a widening PP [30]. These changes suggest that large artery stiffness becomes the predominant haemodynamic factor driving increases in SBP in individuals aged  $>60$  years, while peripheral vascular resistance drives BP in younger individuals [30].

As we hypothesized, the greatest reductions in PP were observed in the oldest patients and in those with the highest SBP at baseline. MAP was reduced in all the subgroups, with no greater reduction in patients with higher age or SBP at baseline. This is explained by the dominance of DBP in the measurement of MAP, which means that MAP reflects small artery resistance and cardiac output to a greater extent than PP. It




Figure 2. Continued

appears, therefore, that empagliflozin is efficacious across the entire age range but its effects may differ with age; for example, in younger patients, BP reduction may be mediated via effects on small artery resistance and, in the elderly, largely via effects on large artery stiffness. The reduction in the DP (or RPP), a marker of cardiac workload, observed with empagliflozin was driven by reduction in SBP; empagliflozin had a neutral effect on heart rate in this analysis, consistent with the results of previous trials in patients with T2DM and with the results of a study on the effects of empagliflozin on heart rate variability in patients with T1DM [29]. The reduction in the DP (or RPP) is intriguing from the perspective of its prognostic impact on CV and total mortality, but also from a congestive heart failure perspective, and it is tempting to speculate that empagliflozin may reduce hospitalization for heart failure. Interestingly, in a

16-week study in a diabetic hypertensive rat model of heart failure, empagliflozin was observed to have beneficial effects on cardiac morphology and function [31].

The observation that empagliflozin has an impact on the vasculature without increasing pulse rate is interesting from a CV perspective and could be interpreted as a consequence of a relative reduction in the sympathetic nervous system tonus. Although neurohormonal factors could also play a role, this notion is supported by mechanistic data from normotensive patients with T2DM in whom no apparent changes in muscle sympathetic nerve activity, measured using microneurography, were observed, despite clinical benefits with regard to BP and weight [32].

Reductions in SBP and DBP have consistently been observed with the use of SGLT2 inhibitors in patients with T2DM


**Table 1.** Subgroup analyses of differences between empagliflozin and placebo in changes from baseline in markers of arterial stiffness and vascular resistance.

Subgroup	Placebo n	Empagliflozin n	Adjusted mean (95% CI) differences for empagliflozin vs placebo in change from baseline in:			
			SBP, mmHg	DBP, mmHg	PP, mmHg	MAP, mmHg
<b>Cohort 1</b>						
<b>Baseline age</b>						
<50 years	31	65	-3.5 (-7.0, -0.0)	-1.6 (-3.6, 0.4)	-1.8 (-4.0, 0.4)	-2.3 (-4.6, 0.1)
p value			<0.050	0.111	0.105	0.063
50 to <65 years	154	313	-4.3 (-5.8, -2.7)	-1.7 (-2.6, -0.8)	-2.4 (-3.4, -1.5)	-2.6 (-3.7, -1.5)
p value			<0.001	<0.001	<0.001	<0.001
65 to <75 years	79	136	-3.1 (-5.4, -0.9)	-1.2 (-2.5, 0.1)	-2.0 (-3.4, -0.6)	-1.9 (-3.4, -0.3)
p value			0.006	0.073	0.006	0.018
≥75 years	7	38	-4.4 (-11.0, 2.2)	-0.6 (-4.4, 3.2)	-4.4 (-8.5, -0.4)	-1.7 (-6.2, 2.8)
p value			0.189	0.748	0.033	0.462
Interaction p value			0.865	0.874	0.665	0.881
<b>Sex</b>						
Male	168	327	-3.7 (-5.2, -2.1)	-1.3 (-2.1, -0.4)	-2.3 (-3.3, -1.4)	-2.1 (-3.1, -1.0)
p value			<0.001	0.005	<0.001	<0.001
Female	103	225	-4.2 (-6.0, -2.3)	-1.9 (-3.0, -0.8)	-2.2 (-3.4, -1.0)	-2.7 (-4.0, -1.4)
p value			<0.001	<0.001	<0.001	<0.001
Interaction p value			0.681	0.379	0.875	0.461
<b>Baseline SBP</b>						
SBP <130 mmHg	130	276	-2.4 (-4.1, -0.7)	-1.1 (-2.1, -0.1)	-1.4 (-2.5, -0.4)	-1.7 (-2.8, -0.5)
p value			0.006	0.024	0.007	0.005
SBP 130–140 mmHg	85	147	-4.9 (-7.1, -2.7)	-2.1 (-3.3, -0.8)	-2.9 (-4.2, -1.5)	-3.0 (-4.5, -1.6)
p value			<0.001	0.001	<0.001	<0.001
SBP >140 mmHg	56	129	-4.6 (-7.3, -2.0)	-1.4 (-2.9, 0.1)	-3.2 (-4.8, -1.7)	-2.5 (-4.2, -0.7)
p value			<0.001	0.059	<0.001	0.005
Interaction p value			0.153	0.494	0.092	0.342
<b>Cohort 2</b>						
<b>Baseline age</b>						
<50 years	222	464	-3.3 (-5.0, -1.5)	-1.1 (-2.2, 0.0)	-2.2 (-3.5, -0.8)	-1.8 (-3.0, -0.6)
p value			<0.001	0.053	0.002	0.003
50 to <65 years	459	871	-3.4 (-4.6, -2.2)	-1.8 (-2.6, -1.0)	-1.6 (-2.6, -0.6)	-2.3 (-3.2, -1.5)
p value			<0.001	<0.001	0.001	<0.001
65 to <75 years	119	276	-4.0 (-6.3, -1.6)	-0.3 (-1.8, 1.1)	-3.6 (-5.5, -1.8)	-1.6 (-3.2, 0.0)
p value			0.001	0.649	<0.001	0.053
≥75 years	25	41	-8.3 (-13.7, -2.9)	-0.1 (-3.5, 3.3)	-8.2 (-12.4, -3.9)	-2.8 (-6.5, 0.9)
p value			0.003	0.955	<0.001	0.135
Interaction p value			0.365	0.284	0.011	0.788
<b>Sex</b>						
Male	424	927	-3.8 (-5.1, -2.6)	-1.5 (-2.3, -0.7)	-2.3 (-3.3, -1.3)	-2.3 (-3.2, -1.5)
p value			<0.001	<0.001	<0.001	<0.001
Female	401	725	-3.4 (-4.7, -2.0)	-1.2 (-2.0, -0.3)	-2.2 (-3.2, -1.1)	-1.9 (-2.8, -1.0)
p value			<0.001	0.006	<0.001	<0.001
Interaction p value			0.598	0.546	0.851	0.526
<b>Baseline SBP</b>						
SBP <130 mmHg	462	891	-2.6 (-3.9, -1.3)	-0.8 (-1.6, -0.1)	-1.7 (-2.7, -0.7)	-1.4 (-2.2, -0.6)
p value			<0.001	0.033	<0.001	0.001
SBP 130–140 mmHg	201	412	-4.0 (-5.9, -2.1)	-1.7 (-2.8, -0.5)	-2.4 (-3.9, -0.9)	-2.5 (-3.7, -1.2)
p value			<0.001	0.005	0.001	<0.001
SBP >140 mmHg	162	349	-6.3 (-8.4, -4.2)	-2.3 (-3.6, -1.1)	-3.6 (-5.3, -2.0)	-3.5 (-4.9, -2.2)
p value			<0.001	<0.001	<0.001	<0.001
Interaction p value			0.013	0.123	0.124	0.027

CI, confidence interval; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; SBP, systolic blood pressure.

Data are adjusted mean (95% CI) using analysis of covariance (ANCOVA) with LOCF imputation in randomized patients who received ≥1 dose of study medication and had a baseline Glycated haemoglobin value (both cohorts) and baseline mean 24-h SBP value (cohort 1 only). Measurements were based on mean 24-h ABPM in cohort 1 and seated office measurements in cohort 2. Data after initiation of glucose-lowering rescue therapy were set to missing.





**Figure 3.** Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) by sex. (A) SBP, DBP, PP and MAP at baseline and at week 12 in cohort 1. (B) SBP, DBP, PP and MAP at baseline and at week 24 in cohort 2. Baseline data are mean  $\pm$  standard error (s.e.), week 12 or 24 data are adjusted mean  $\pm$  s.e. based on analysis of covariance (ANCOVA) in the full analysis set using last observation carried forward (LOCF) imputation. In cohort 1, measurements were based on mean 24-h ambulatory blood pressure monitoring (ABPM) and in cohort 2, they were based on seated office measurements. \*\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$  for adjusted mean differences for empagliflozin versus placebo in change from baseline based on ANCOVA with LOCF imputation.

[33], but no data in humans have been published on reductions in arterial stiffness or vascular resistance with SGLT2 inhibitors other than empagliflozin. As no other classes of glucose-lowering drugs, including dipeptidyl peptidase-4 inhibitors and GLP-1 receptor analogues, have shown similar findings, the observed improvements in arterial stiffness and vascular resistance could be a unique phenomenon for empagliflozin, which could have major implications for vascular health and CV prognosis.

The mechanisms by which empagliflozin reduces BP and arterial stiffness are not fully understood, but may be related to improved glycaemic control, weight loss, volume contraction as a result of osmotic diuresis or reduced oxidative stress [29,33–36]. In a rat model, empagliflozin was further shown to normalize endothelial function, reduce oxidative stress in aortic vessels, reverse a pro-inflammatory phenotype, and improve AGE/RAGE signalling [37], all pathways of potential importance to a reduction in arterial stiffness [36]. In addition, in a




Figure 3. Continued


mouse model of obesity and T2DM, empagliflozin ameliorated pericoronary arterial fibrosis, coronary arterial thickening and cardiac macrophage infiltration, effects that are associated with attenuation of oxidative stress in CV tissue [38].

In this analysis, events consistent with volume depletion were rare and no such events were reported in patients aged  $\geq 75$  years; however, the potential for volume depletion in vulnerable patients such as the elderly, those with renal impairment, those with low SBP and those receiving diuretics is acknowledged in the prescribing information for SGLT2 inhibitors [39–41] and appropriate caution should be exercised in the use of empagliflozin in such patients in clinical practice.

Strengths of the analyses presented in this manuscript include the large number of patients analysed (cohort 2) and

the use of 24-h ABPM in patients with hypertension (cohort 1). Limitations include the *post hoc* nature of the analyses, the relatively small number of patients in the older age groups, that the analyses did not account for multiple testing, and the short exposure period to the drug (12 or 24 weeks). In addition, there were few Asian patients with advanced hypertension, which limits the generalizability of our findings to this population.

Indirect evidence suggests that reductions in arterial stiffness and vascular resistance may reduce CV risk beyond BP reduction [42,43]. Reductions in BP and arterial stiffness are two of the effects of SGLT2 inhibitors that might ameliorate CV risk and heart failure in patients with T2DM [44]. The effects of empagliflozin on CV and microvascular outcomes are being investigated in the EMPA-REG OUTCOME<sup>®</sup> trial



**Figure 4.** Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) by subgroups of baseline SBP. (A) SBP, DBP, PP and MAP at baseline and at week 12 in cohort 1. (B) SBP, DBP, PP and MAP at baseline and at week 24 in cohort 2. Baseline data are mean  $\pm$  standard error (s.e.), week 12 or 24 data are adjusted mean  $\pm$  s.e. based on analysis of covariance (ANCOVA) in the full analysis set using last observation carried forward (LOCF) imputation. In cohort 1, measurements were based on mean 24-h ambulatory blood pressure monitoring (ABPM) and in cohort 2, they were based on seated office measurements. \*\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$  for adjusted mean differences for empagliflozin versus placebo in change from baseline based on ANCOVA with LOCF imputation.

(NCT01131676) [45], which will report results in the second half of 2015.

### Acknowledgements

The studies that provided data for these analyses were funded by Boehringer Ingelheim and Eli Lilly and Company. Medical writing assistance, supported financially by Boehringer

Ingelheim, was provided by Clare Ryles and Wendy Morris of Fleishman-Hillard Group Ltd during the preparation of this manuscript.

### Conflict of Interest

R. C. has received consulting fees from Pfizer, Bristol Myers Squibb, Merck Sharp and Dohme, Takeda, Boston Scientific and Boehringer Ingelheim. I. T. has received consulting




Figure 4. Continued.

fees/payments for lectures and support for travel to meetings from Boehringer Ingelheim. C. C. has received grants from Accumetrics, Arisaph, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck and Takeda, and consulting fees from Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Essentialis, GlaxoSmithKline, Kowa, Merck, Takeda, Lipimedix, Pfizer, Regeneron and Sanofi. S. C., H. J. W., U. C. B. and O. E. J. are employees of Boehringer Ingelheim.

O. E. J. planned the study. U. C. B. and O. E. J. contributed to the study design and interpretation of data and writing of the manuscript. R. C., I. T., and C. P. C. contributed to the acquisition and interpretation of data and reviewed/edited the

manuscript. S. C. and H. J. W. contributed to the interpretation of data and reviewed/edited the manuscript. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version.

### Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Changes in blood pressure and heart rate in cohorts 1 and 2.

Table S1. Patient demographics and baseline characteristics.

## References

1. American Diabetes Association. Standards of medical care in diabetes-2015. *Diabetes Care* 2015; **38**(Suppl. 1): S1–93.
2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010; **375**: 2215–2222.
3. [ESC/EASD] Task Force on Diabetes, Pre-diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD), Rydén L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD—summary. *Diab Vasc Dis Res* 2014; **11**: 133–173.
4. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. *Circulation* 2003; **108**: 1527–1532.
5. Hsueh WA, Wyne K. Renin-angiotensin-aldosterone system in diabetes and hypertension. *J Clin Hypertens (Greenwich)* 2011; **13**: 224–237.
6. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. *BMC Cardiovasc Disord* 2013; **13**: 13.
7. Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. *Endocrinol Metab Clin North Am* 2014; **43**: 103–122.
8. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. *Diabetologia* 2008; **51**: 527–539.
9. Wagenseil JE, Mecham RP. Elastin in large artery stiffness and hypertension. *J Cardiovasc Transl Res* 2012; **5**: 264–273.
10. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol* 2010; **55**: 1318–1327.
11. Nilsson PM, Boutouyrie P, Cunha P et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. *J Hypertens* 2013; **31**: 1517–1526.
12. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systematic meta-analysis. *Heart Fail Rev* 2015; **20**: 291–303.
13. Jung CH, Jung SH, Kim KJ et al. Differential associations of central and brachial blood pressure with carotid atherosclerosis and microvascular complications in patients with type 2 diabetes. *BMC Cardiovasc Disord* 2014; **14**: 23.
14. Nilsson PM, Cederholm J, Eeg-Olofsson K et al. Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). *Diabetes Metab* 2009; **35**: 439–446.
15. Yu D, Simmons D. Association between pulse pressure and risk of hospital admissions for cardiovascular events among people with type 2 diabetes: a population-based case-control study. *Diabet Med* 2015; **32**: 1201–1206.
16. Kodama S, Horikawa C, Fujihara K et al. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. *Am J Cardiol* 2014; **113**: 1058–1065.
17. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. *Eur Heart J* 2010; **31**: 1865–1871.
18. Dolan E, Li Y, Thijs L et al. Ambulatory arterial stiffness index: rationale and methodology. *Blood Press Monit* 2006; **11**: 103–105.
19. Kollias A, Stergiou GS, Dolan E, O'Brien E. Ambulatory arterial stiffness index: a systematic review and meta-analysis. *Atherosclerosis* 2012; **224**: 291–301.
20. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. *Am J Hypertens* 1999; **12**: 505–555.
21. Inoue R, Ohkubo T, Kikuya M et al. Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study. *Am J Hypertens* 2012; **25**: 568–575.
22. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. *Diabetes Obes Metab* 2012; **14**: 83–90.
23. Roden M, Weng J, Eilbracht J et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2013; **1**: 208–219.
24. Häring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care* 2014; **37**: 1650–1659.
25. Häring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care* 2013; **36**: 3396–3404.
26. Kovacs CS, Seshiah V, Swallow R et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. *Diabetes Obes Metab* 2014; **16**: 147–158.
27. Tikkanen I, Narko K, Zeller C et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. *Diabetes Care* 2015; **38**: 420–428.
28. Nishimura R, Tanaka Y, Koizumi K et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. *Cardiovasc Diabetol* 2015; **14**: 11.
29. Cherney DZ, Perkins BA, Soleymanlou N et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. *Cardiovasc Diabetol* 2014; **13**: 28.
30. Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. *J Hypertens Suppl* 1999; **17**: S29–36.
31. Younis F, Hollander K, Mayoux E et al. Effect of prophylactic treatment with empagliflozin on cardiac function and diabetes in CRDH rats. *Diabetes* 2014; **63**(Suppl. 1): A273 [1056-P].
32. Jordan J, Tank J, Heusser K et al. Empagliflozin (EMPA) has no discernable effect on muscle sympathetic nerve activity (MSNA) in patients with type 2 diabetes (T2DM) despite reductions in blood pressure (BP) and weight. *Diabetes* 2014; **63**: A265 (Suppl. 1).
33. Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. *J Am Soc Hypertens* 2014; **8**: 262–275.
34. Dengo AL, Dennis EA, Orr JS et al. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. *Hypertension* 2010; **55**: 855–861.
35. Ferreira MT, Leite NC, Cardoso CRL, Salles GF. Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycaemic control: the Rio de Janeiro type 2 diabetes cohort study. *Diabetes Care* 2015; **38**: 897–904.
36. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. *Hypertension* 2002; **40**: 804–809.
37. Oelze M, Kröller-Schön S, Welsch P et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. *PLoS One* 2014; **9**: e112394.
38. Lin B, Koibuchi N, Hasegawa Y et al. Glycaemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive

- dysfunction in obese and type 2 diabetic mice. *Cardiovasc Diabetol* 2014; **13**: 148.
39. AstraZeneca Pharmaceuticals LLP. Farxiga™ (dapagliflozin) US prescribing information. 2014.
40. Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance® (empagliflozin) US prescribing information. 2014.
41. Janssen Pharmaceuticals Inc. Invokana™ (canagliflozin) US prescribing information. 2014.
42. Frishman WH. Increased vascular compliance/decreased cardiovascular risk: what the studies tell us. *Heart Dis* 2000; **2**: 384–388.
43. Cameron JD, Asmar R, Struijker-Boudier H et al. Current and future initiatives for vascular health management in clinical practice. *Vasc Health Risk Manag* 2013; **9**: 255–264.
44. Inzucchi SE, Zinman B, Wanner C et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. *Diab Vasc Dis Res* 2015; **12**: 90–100.
45. Zinman B, Inzucchi SE, Lachin JM et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). *Cardiovasc Diabetol* 2014; **13**: 102.